Alexander R. Macalalad

Health Data Research UK — United Kingdom

Medicine · Health Sciences

14h-index1.1kcitations44works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(11), Cancer Treatment and Pharmacology(10), Advanced Breast Cancer Therapies(9), Chronic Lymphocytic Leukemia Research(7), Chronic Myeloid Leukemia Treatments(6)

Publications44 total

Connecting Digital Health to High-Value Care: A Quasi-Experimental Evaluation of the Impact of Care Guides with the Castlight App on Healthcare Costs and Utilization
2025
A holistic approach for suppression of COVID-19 spread in workplaces and universities
PLoS ONE·2021· 17 citedOpen Access
A holistic approach for suppression of COVID-19 spread in workplaces and universities
2020· 5 citedOpen Access
Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients
Advances in Therapy·2017· 6 cited
Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study
Advances in Therapy·2017· 17 cited
Abstract 2269: Comparative effectiveness of everolimus + endocrine therapy vs endocrine monotherapy among postmenopausal women with HR+/HER2- advanced breast cancer: a multicountry retrospective chart review
Cancer Research·2016· 1 cited
Overall survival in patients with glioblastoma before and after bevacizumab approval.
Journal of Clinical Oncology·2016· 7 cited
The economic burden of brain metastasis among lung cancer patients in the United States
Journal of Medical Economics·2016· 49 cited
3114 Testing and treatment practice of oncologists managing ALK+ NSCLC: international physician survey across four regions
European Journal of Cancer·2015
Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection
JAMA Oncology·2015· 20 citedOpen Access
Treatment, overall survival, and costs in patients with<i>ALK</i>-positive non-small-cell lung cancer after crizotinib monotherapy
Current Medical Research and Opinion·2015· 24 cited
FRI0129 Assessing the Economic Impact of Comprehensive Disease Control on Total Direct Medical Expenditures for Rheumatoid Arthritis
Annals of the Rheumatic Diseases·2015· 1 cited
Treatment patterns of Endocrine Therapy and Chemotherapy among post-menopausal Women with HR+/HER2- metastatic Breast Cancer
Value in Health·2015
ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer
Cancer Epidemiology·2015· 21 cited
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data
Current Medical Research and Opinion·2015· 20 cited
Economic Consequences of Cytomegalovirus Disease Among Stem Cell Transplant Recipients
Biology of Blood and Marrow Transplantation·2015· 3 citedOpen Access
The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas
Current Medical Research and Opinion·2015· 8 cited
Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2-Metastatic Breast Cancer
Breast Cancer Basic and Clinical Research·2015· 4 citedOpen Access
BM-19 * SYMPTOMATIC AND ECONOMIC BURDEN OF BRAIN METASTASES IN PATIENTS WITH ALK+ NSCLC
Neuro-Oncology·2014· 3 citedOpen Access
Description of ALK+ NSCLC Patient Characteristics and ALK Testing Patterns
International Journal of Radiation Oncology*Biology*Physics·2014Open Access
page 1 of 3Next →

Frequent Co-authors

Eric Q. Wu(21), Medha Sasané(15), Annie Guérin(14), James Signorovitch(10), Kenneth W. Culver(8), Yanni Hao(8), Philip Galebach(8), A. Guérin(7), Peggy L. Lin(7), Erika Ohashi(7), Caroline Kelley(7), E.Q. Wu(6), Lei Chen(5), Heather A. Wakelee(5), Andrew Kageleiry(5), Jinlin Song(5), Suleiman Massarweh(5), K. Dea(4), Roy Nitulescu(4), J. Zhang(4)